CN1424063A - Oral medicinal composition for treating diabetes - Google Patents
Oral medicinal composition for treating diabetes Download PDFInfo
- Publication number
- CN1424063A CN1424063A CN 02128052 CN02128052A CN1424063A CN 1424063 A CN1424063 A CN 1424063A CN 02128052 CN02128052 CN 02128052 CN 02128052 A CN02128052 A CN 02128052A CN 1424063 A CN1424063 A CN 1424063A
- Authority
- CN
- China
- Prior art keywords
- radix
- medicine
- group
- combination
- oral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 33
- 239000000203 mixture Substances 0.000 title claims description 40
- 239000003814 drug Substances 0.000 claims abstract description 125
- 229940079593 drug Drugs 0.000 claims description 82
- 229940126701 oral medication Drugs 0.000 claims description 22
- 239000004615 ingredient Substances 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- 239000007788 liquid Substances 0.000 claims description 16
- 239000009636 Huang Qi Substances 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 14
- 239000000284 extract Substances 0.000 claims description 12
- 239000002994 raw material Substances 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 5
- 210000004369 blood Anatomy 0.000 abstract description 79
- 239000008280 blood Substances 0.000 abstract description 78
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 34
- 235000012000 cholesterol Nutrition 0.000 abstract description 17
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract description 12
- 239000000463 material Substances 0.000 abstract description 4
- 244000170916 Paeonia officinalis Species 0.000 abstract 1
- 235000006484 Paeonia officinalis Nutrition 0.000 abstract 1
- 241000405414 Rehmannia Species 0.000 abstract 1
- 240000007164 Salvia officinalis Species 0.000 abstract 1
- 229940107666 astragalus root Drugs 0.000 abstract 1
- 235000005412 red sage Nutrition 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 45
- 239000008103 glucose Substances 0.000 description 45
- 230000000694 effects Effects 0.000 description 34
- 238000012360 testing method Methods 0.000 description 30
- 241000700159 Rattus Species 0.000 description 27
- 241000699670 Mus sp. Species 0.000 description 18
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 18
- 238000000605 extraction Methods 0.000 description 15
- 238000000034 method Methods 0.000 description 14
- 230000007812 deficiency Effects 0.000 description 13
- 208000011580 syndromic disease Diseases 0.000 description 13
- 210000003743 erythrocyte Anatomy 0.000 description 11
- 230000037396 body weight Effects 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 201000001421 hyperglycemia Diseases 0.000 description 10
- 210000002784 stomach Anatomy 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- 210000002700 urine Anatomy 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 230000009467 reduction Effects 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 235000012054 meals Nutrition 0.000 description 7
- 229930182837 (R)-adrenaline Natural products 0.000 description 6
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 6
- 235000009508 confectionery Nutrition 0.000 description 6
- 229960005139 epinephrine Drugs 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 description 6
- 206010021143 Hypoxia Diseases 0.000 description 5
- 230000002776 aggregation Effects 0.000 description 5
- 238000004220 aggregation Methods 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 230000007954 hypoxia Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 230000009182 swimming Effects 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 201000005577 familial hyperlipidemia Diseases 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000003304 gavage Methods 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000000630 rising effect Effects 0.000 description 4
- 238000010254 subcutaneous injection Methods 0.000 description 4
- 239000007929 subcutaneous injection Substances 0.000 description 4
- 230000035922 thirst Effects 0.000 description 4
- 239000004366 Glucose oxidase Substances 0.000 description 3
- 108010015776 Glucose oxidase Proteins 0.000 description 3
- 102000015779 HDL Lipoproteins Human genes 0.000 description 3
- 108010010234 HDL Lipoproteins Proteins 0.000 description 3
- 102000001554 Hemoglobins Human genes 0.000 description 3
- 108010054147 Hemoglobins Proteins 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000002651 drug therapy Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 229940116332 glucose oxidase Drugs 0.000 description 3
- 235000019420 glucose oxidase Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 210000004279 orbit Anatomy 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000029058 respiratory gaseous exchange Effects 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 210000002435 tendon Anatomy 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- -1 using always Substances 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 2
- 239000004380 Cholic acid Substances 0.000 description 2
- 241000756943 Codonopsis Species 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- 206010013954 Dysphoria Diseases 0.000 description 2
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 2
- 229960002471 cholic acid Drugs 0.000 description 2
- 235000019416 cholic acid Nutrition 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229960004580 glibenclamide Drugs 0.000 description 2
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 235000021590 normal diet Nutrition 0.000 description 2
- 238000007410 oral glucose tolerance test Methods 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- YKRGDOXKVOZESV-UHFFFAOYSA-N paeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(CO)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-UHFFFAOYSA-N 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- 239000008517 radix Trichosanthis Substances 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 235000019615 sensations Nutrition 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000012109 statistical procedure Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- ATADHKWKHYVBTJ-FVGYRXGTSA-N (R)-adrenaline hydrochloride Chemical compound [H+].[Cl-].CNC[C@H](O)C1=CC=C(O)C(O)=C1 ATADHKWKHYVBTJ-FVGYRXGTSA-N 0.000 description 1
- ODINCKMPIJJUCX-UHFFFAOYSA-N Calcium oxide Chemical compound [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 208000007241 Experimental Diabetes Mellitus Diseases 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 241001608711 Melo Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000382353 Pupa Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000282894 Sus scrofa domesticus Species 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 208000031975 Yang Deficiency Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000004308 accommodation Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229930003935 flavonoid Chemical class 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000012633 leachable Substances 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229940074869 marquis Drugs 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000004531 microgranule Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- VBUNOIXRZNJNAD-UHFFFAOYSA-N ponazuril Chemical compound CC1=CC(N2C(N(C)C(=O)NC2=O)=O)=CC=C1OC1=CC=C(S(=O)(=O)C(F)(F)F)C=C1 VBUNOIXRZNJNAD-UHFFFAOYSA-N 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Chemical class 0.000 description 1
- 229930182490 saponin Chemical class 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
An orally-applied Chinese medicine for treating diabetes by lowering blood viscosity and reducing triglyceride, cholesterol and blood sugar is prepared from 11 Chinese-medicinal materials including astragalus root, rehmannia root, red peony root, red sage root, etc.
Description
Technical field
The present invention relates to a kind of is the combination of oral medication that the treatment diabetes of effective medicinal ingredient are used with natural drug.
Background technology
Diabetes are a kind of common multiple diseases, and the health of human body is seriously influenced and damages.With traditional natural drug or its compositionss such as Chinese medicine, or also being aided with other drug simultaneously and treating, is present Therapeutic Method a kind of important and commonly used.In existing data, can be used for the Chinese medicine or the existing many reports of its compositions for the treatment of diabetes.For example, application number is to have reported the treatment diabetes Chinese medicine of forming with many ingredients such as Radix Codonopsis, the Radix Astragali, Rhizoma Dioscoreae, the Rhizoma Anemarrhenae, Radix Trichosanthis, Radix Puerariae, Radix Scrophulariae, Radix Ophiopogonis, Fructus Corni, Fructus Lycii, Fructus Schisandrae Chinensis, Rhizoma Coptidis, Radix Salviae Miltiorrhizae, Radix Achyranthis Bidentatae, Semen Platycladi, Fructus Rubi, the Radix Rehmanniae, Radix Glycyrrhizae in 99110758 the Chinese patent open source literature; Application number is to have reported a kind of by tens of Remedies for diabetes of distinguishing the flavor of and becoming to be grouped into such as Radix Astragali, the Radix Rehmanniae, Radix Salviae Miltiorrhizae, Rhizoma Dioscoreae, Semen Litchi, Radix Scrophulariae, Rhizoma Atractylodis, Fructus Lycii, Fructus Mume, Stigma Maydis, Fructus Schisandrae Chinensis, Radix Trichosanthis, Pedicellus Melo, Cortex Cinnamomi, Pupa bombycis, Ramulus Euonymi, Concha Meretricis seu Cyclinae, Endothelium Corneum Gigeriae Galli, Radix Puerariae, Folium Mori, Rhizoma Polygonatis in 00108421 the Chinese patent open source literature.In addition, be respectively 01113998,01103594 at application number, 98111177,95102128,94100453, in many Chinese patent open source literatures such as 00123304,00129433, also all reported the pharmaceutical composition that can be used for treating diabetes of different composition forms respectively.
Summary of the invention
According to above-mentioned situation, it is effective ingredient with the natural drug that the present invention will provide a kind of, and a large amount of evidences of warp are except that having satisfied blood sugar lowering effect, also have rising that reduces plasma viscosity, the rising of reduction erythrocyte aggregation index and erythrocyte rigidity index and the effect that reduces serum levels of triglyceride and cholesterol simultaneously, wherein act as significant combination of oral medication with cholesterol reducing especially.
The present invention treats the combination of oral medication of diabetes, be to be the active drug composition, and mix composition with the auxiliary adding ingredient of acceptable in oral drug preparation with the Radix Astragali, the Radix Rehmanniae, Radix Paeoniae Rubra, Radix Salviae Miltiorrhizae, Radix Achyranthis Bidentatae, Radix Ophiopogonis, Radix Puerariae, Folium Mori, Rhizoma Coptidis, Rhizoma Polygonati and Herba Epimedii.Wherein the weight portion ratio of each active drug composition is:
Radix Astragali 19-30, Radix Rehmanniae 20-31, Radix Paeoniae Rubra 20-31, Radix Salviae Miltiorrhizae 19-30, Radix Achyranthis Bidentatae 11-18,
Radix Ophiopogonis 11-18, Radix Puerariae 12-20, Folium Mori 12-20, Rhizoma Coptidis 3-6, Rhizoma Polygonati 12-18,
Herba Epimedii 16-22.
The weight portion ratio of said each active drug composition can also further be adopted as on the basis of above-mentioned composition form:
Radix Astragali 22-26, Radix Rehmanniae 23-29, Radix Paeoniae Rubra 23-29, Radix Salviae Miltiorrhizae 22-26, Radix Achyranthis Bidentatae 13-17,
Radix Ophiopogonis 13-17, Radix Puerariae 13-18, Folium Mori 13-18, Rhizoma Coptidis 4-6, Rhizoma Polygonati 14-17,
Herba Epimedii 18-22.
The weight portion ratio form that can adopt especially is:
Radix Astragali 23-25, Radix Rehmanniae 25-27, Radix Paeoniae Rubra 25-27, Radix Salviae Miltiorrhizae 23-25, Radix Achyranthis Bidentatae 14-15,
Radix Ophiopogonis 14-15, Radix Puerariae 14-17, Folium Mori 14-17, Rhizoma Coptidis 4-5, Rhizoma Polygonati 14-16,
Herba Epimedii 19-21.
On the basis of above-mentioned active drug composition form, for being convenient to production and processing more, generally speaking can be with each the active drug composition in the above-mentioned combination of oral medication of the present invention, adopt the identical or close composition of usage ratio amount is classified as one group mode divides into groups.Wherein, the Radix Astragali, the Radix Rehmanniae, Radix Paeoniae Rubra and Radix Salviae Miltiorrhizae divide for using first of basic identical or close weight portion to form; Radix Achyranthis Bidentatae, Radix Ophiopogonis, Radix Puerariae, Folium Mori, Rhizoma Polygonati and Herba Epimedii divide for using second of basic identical or close weight portion to form.During use, weight portion of the one-component during each form to divide is adopted as first group one-component: second group one-component: Rhizoma Coptidis equals or is similar to 5: 3: 1 proportion of composing form.
Diabetes are a kind of common endocrine metabolism diseases, belong to the category of " quenching one's thirst " disease in Chinese medicine, and also can further have the upper, middle and lower three types of diabetes branch and the dryness of the lung, gastric heat, suffer from a deficiency of the kidney not.Symptom more than three in its clinical manifestation often exists simultaneously, and the weight difference on the degree is only arranged.Theory of Chinese medical science thinks, this onset of disease, and to belong to scorching be main, course of disease elder, and the then deficiency of YIN and scorching cross-reference, disease is then attached most importance to the deficiency of YIN for a long time, and intenseness of heat consumption gas and cause deficiency of both QI and YIN or deficiency of both YIN and YANG very then, yang deficiency cold coagulation cause that sering hinders numbness and the card that becomes blood stasis.The base therapy principle and the method for traditional medicine are that supplementing QI and nourishing YIN and blood circulation promoting and blood stasis dispelling and/or the kidney invigorating are with using.Medicine commonly used has Radix Adenophorae (Radix Glehniae), the Radix Rehmanniae, Radix Ophiopogonis, Rhizoma Coptidis, Radix Puerariae, Radix Codonopsis, the Rhizoma Anemarrhenae, Radix Salviae Miltiorrhizae, Radix Achyranthis Bidentatae, SIWU TANG class etc.
According to the theory of Chinese medicine, in each active drug composition of forming aforementioned pharmaceutical compositions of the present invention, the Radix Astragali, sweet in the mouth is warm in nature, with the passing of time QI invigorating to delay at diabetes, and intenseness of heat consumes the pathogenesis of gas, and other activating blood and removing stasis drugs during cooperation is formed are to reach the effect of benefiting qi and removing blood stasis; The Radix Rehmanniae, i.e. Radix Rehmanniae, the sweet in the mouth bitter cold, replenishing YIN and removing heat, with main pathogenesis at interior-heat caused by deficiency of YIN, with the Radix Astragali be monarch drug in the active drug composition altogether.Syndrome of blood stasis is one of principal indication marquis of medicine of the present invention, and the formation of diabetes syndrome of blood stasis is scorching with the deficiency of YIN, and it is main that Tianjin consumption liquid that burns, the moon thanks to can not carry due to the blood operation, so with the Radix Paeoniae Rubra and the Radix Salviae Miltiorrhizae compatibility of clearing away heat and cooling blood blood stasis dispelling, the merit of playing cooling blood and removing stasis altogether; Radix Achyranthis Bidentatae, wherein special recommendation is Radix Achyranthis Bidentatae, property is flat, bitter in the mouth, acid, can heat conduction and conducting blood to flow downwards to fall the fire of superinverse, again can invigorating the liver and kidney, promoting blood circulation, with Radix Paeoniae Rubra and Radix Salviae Miltiorrhizae be ministerial drug altogether.Radix Ophiopogonis, cold nature, sweet and slightly bitter taste, yin nourishing clears away heart-fire; Radix Puerariae is cool in nature, sweet in the mouth suffering, analgesic promoting the production of body fluid; Folium Mori, bitter in the mouth is sweet cold, clearing away heat and cooling blood; The Rhizoma Coptidis bitter in the mouth is cold in nature, clearing away heat-fire, and these four kinds become phase-splitting 5, are the effect of heat clearing away YIN nourishing altogether.Syndrome of deficiency of both qi and yin and deficiency syndrome of both YIN and YANG are common clinically can not completely divide, the trend that syndrome of deficiency of both qi and yin Chang Youxiang deficiency of both YIN and YANG transforms, so select acrid in the mouth again for use and temperature, the Herba Epimedii of kidney invigorating and YANG supporting and sweet in the mouth and put down, Rhizoma Polygonati two ingredients of nourishing kidney-yin mutually 5, both kidney-replenishings, nourishing kidney-yin again, coordination of YIN and YANG, the effect that being altogether reinforces the kidney protects kidney.These medicines are the adjuvant drug composition in the prescription altogether.
The present invention is foundation with the theory of Chinese medical science, adopt above-mentioned active drug composition to cooperatively interact and consist of a complete pharmaceutical composition, be when research and having compiled the speciality of successive dynasties tradition name sides, combine the achievement of modern scientific research and thinking again and form.Various result of the tests show, its blood sugar lowering, blood fat reducing and improve the definite effect of blood flow function show that the monarch and his subjects' adjuvant drug that its active drug is formed cooperates in order, can be applicable to the treatment of syndrome of blood stasis of holding concurrently of diabetes deficiency of both QI and YIN effectively.
The result of modern scientific research shows, the physiologically active ingredient in the above-mentioned drug effect ingredient of the present invention, and promptly effective medicinal ingredient mainly contains polysaccharide, flavonoid, Saponin class, phenols, aminoacid, alkaloid etc., all has better water solubility.Therefore; pharmaceutical composition according to above-mentioned active drug composition form of the present invention; when being prepared into oral formulations; to each used active drug composition; both can be for directly having met granule or the microgranule that corresponding oral formulations requires granularity by what each corresponding natural crude drug obtained, also can adopt with the medicine that is equivalent to described part by weight relation is the form of the water extract composition that obtains of raw material.When adopting the latter's water extract composition form, after particularly can adopting decocting mode commonly used or obtaining the aqueous solution of each ingredient with 80 ℃-100 ℃ hot water circuit extracting mode, the form of extract that becomes through concentration again.Application form to each active drug composition in the said pharmaceutical composition is done above-mentioned variation, can the result of use of medicine not impacted, and the active drug composition of use latter form of extract, can also use and easily be accepted because of the convenient patient of dose that under the prerequisite of same effectively using dosage, can significantly reduce medicine.
As above-mentioned, when adopting the water extract form, be to shorten extraction time and improve extraction efficiency, reduce the workload of concentration, generally to adopt the hot water extraction mode for well.Except that can adopting decocting mode commonly used extracts, can also with reference to as " Japanese Chinese medicine extraction complete set of equipments device " dynamic extraction method of being reported carry out.Its principle and process are to make solvent and be cut into coarse grain and obtain leachable with the medicinal raw material that increases its surperficial contact area fully mixing under the dynamic situation to be incorporated in to extract under the dynamic situation.For example, the active drug of the above-mentioned composition form of the present invention is formed the method that adopts conventional decocting to extract for three times, the dynamic extraction method that all remains unchanged with the granularity of medicine material and total water amount and total extraction time is relatively measured the content that extracts resulting solids and paeoniflorin.Result of the test shows that the extraction effect of two kinds of extracting modes is similar, and the result is as shown in table 1.But also being embodied in, the advantage of dynamic extraction method can more convenient, accurately and strictly control the temperature and time that extracts, reduce the failure loss of effective ingredient and the complexity of operating process (being reduced to disposable operation) as the decocting union operation of inciting somebody to action repeatedly, can improve the ratio of effective ingredient, and the energy energy savings, shorten the production cycle and reduce cost.
The extraction effect that table 1 decocts extracting method and dynamic extraction method compares
| Extracting method | Extractum yield (%) | Content of paeoniflorin (mg/g) |
| Decoct extraction method dynamic extraction method | ????33.40 ????35.16 | 44.5 42.2 |
Adoptable concrete operations and/or using method when above-mentioned effective medicinal ingredient is extracted, both can be that ingredient with said each proportional quantities is a raw material, extract decomposite mode behind its effective medicinal ingredient respectively, also can adopt each medicine material by said proportional quantities mixed after the mode of co-extracted again.Adopt different extraction means, equipment and actual conditionses such as required desirable or best extraction temperature, time when extracting, then can be according to practical situation by a spot of test, can be screened with find.
The active drug composition of above-mentioned composition form according to the present invention, mix with the multi-form auxiliary adding ingredient of acceptable in the oral drug preparation and corresponding the processing after, promptly can be made into the oral drugs of corresponding different dosage forms.As, can be made for the oral drugs of the solid preparation form of tablet commonly used, pill, capsule, various slow release formulations; Also can be made for oral drugs as liquid preparation forms such as water preparation, syrup.Here said auxiliary adding ingredient can be according to different preparations and different, as various disintegrating agents commonly used in solid preparations such as tablet, pill, capsule, excipient, lubricant, binding agent, surfactant, diluent, filler etc.; The surfactant of in liquid preparations such as water preparation or syrup, using always, diluent, antiseptic, stabilizing agent, correctives, thickening agent etc.
According to foregoing,,, obviously can also make modification, replacement or the change of other various ways according to the ordinary skill knowledge and the customary means of this area not breaking away under the basic fundamental thought prerequisite of the present invention.
The specific embodiment of form is described in further detail foregoing of the present invention again by the following examples.But this should be interpreted as that the scope of the above-mentioned theme of the present invention only limits to following example.All technology that realizes based on foregoing of the present invention all belong to scope of the present invention.
The specific embodiment
With part by weight (can allow ±～5% variation) be: the Radix Astragali 25, the Radix Rehmanniae 25, Radix Paeoniae Rubra 25, Radix Salviae Miltiorrhizae 25, Radix Achyranthis Bidentatae 15, Radix Ophiopogonis 15, Radix Puerariae 16, Folium Mori 16, Rhizoma Coptidis 5, Rhizoma Polygonati 15, the crude drug of respectively distinguishing the flavor of of Herba Epimedii 19 is the active drug raw material, and each medicine material pretreatment is become particle diameter is the 3-12 millimeter-sized particles, with～20 times the water yield, extracts 2.5-3 hour with the dynamic extraction method under 95 ± 5 ℃ temperature.With extracting liquid filtering, be concentrated into the extractum of relative density～1.20 (60-65 ℃) after, mix with starch and the dextrin adjuvant that 0.3-1 doubly measures, spray-drying process, granulate sieves, be shaped, and make every gram and contain the solid particle preparation medicine that is equivalent to the effective crude drug composition of 2 grams.Also resulting extractum the corresponding adjuvant that liquid preparation requires can be added, the corresponding liquid oral formulations can be obtained.
With the medicine of above-mentioned gained as trial drug, be mixed with every milliliter of test medicinal liquid that is equivalent to total crude drug amount 10 grams (in the following various tests alleged dose all herewith), Kunming kind white mice with body weight 18-20 gram male and female half and half is an experimental animal, carry out acute toxicity test with the dosage that is equivalent to 450 gram/kg body weight, any toxic reaction does not appear, also do not have animal dead, sacrifice of animal is also dissected after perusal, and main organs is Non Apparent Abnormality also.
Becoming concentration with same test medicinal liquid with distilled water diluting is the suspension of 5 grams per milliliters and 2.5 grams per milliliters (crude drug), as large and small dosage group trial drug (consumption per day that is equivalent to clinical 100 times and 50 times respectively), healthy SD rat to male and female half and half gavages 3-6 month continuously, carrying out long term toxicity test, is contrast with the isometric(al) distilled water.Result of the test shows, the general behavior of experimental animal is movable normal with body weight gain, to hematological indices, the organ coefficient of hepatic and renal function and blood glucose, T-CHOL and main organs does not all have obvious influence, main organs does not have obvious pathology damage, show that medicine does not have overt toxicity, clinical using dosage safety.
Above-mentioned granules medicine is mixed with every milliliter of suspension that contains crude drug 1 gram, 0.5 gram and 0.25 gram respectively with distilled water,, has carried out following relevant pharmacodynamics test as the trial drug of large, medium and small dosage group.
One, the influence of normal animal blood glucose is tested
SD rat with body weight 180-200 gram male and female half and half is an experimental animal, fasting 8 hours, the eye socket vascular plexus is got blood, use determination of glucose oxidase blood glucose, just be equally divided into 5 groups by the euglycemia value, respectively with 20,10 and 5 gram/kg body weight (g/Kg) big, in, low dose (is equivalent to 20 of clinical consumption per day respectively, 10 and 5 times) gavage the above-mentioned test medicinal liquid of the present invention, positive controls gavages glyburide 30mg/kg, irritating the stomach volume is 2 milliliters/100 grams, the normal control group is irritated stomach isometric(al) normal saline, once a day, and successive administration 7 days, fasting before the last administration, after the last administration 1 hour with the method measuring blood sugar of blood extracting.Result of the test is as shown in table 2.
The influence of table 2 pair normal rat blood sugar (mmol/L, n=8, X ± SD)
| Group | Before the administration | After the administration | |
| 1 hour | 3 hours | ||
| Blank | ??5.06±0.80 | ????4.98±0.94 | ????4.83±0.79 |
| Glyburide | ??4.98±0.55 | ????3.45±0.93 ** | ????3.11±0.78 *** |
| Medicine of the present invention (heavy dose) | ??5.00±0.93 | ????4.71±0.94 | ????4.63±0.89 |
| Medicine of the present invention (middle dosage) | ??5.07±0.63 | ????4.84±0.78 | ????4.67±0.94 |
| Medicine of the present invention (low dose) | ??5.06±0.63 | ????5.02±0.89 | ????4.76±0.65 |
Annotate: compare with matched group:
*P＜0.01,
* *P＜0.001
Table 2 result shows, three dosage groups administration of medicine of the present invention 7 days, and rat blood sugar does not have remarkable reduction (comparing P＞0.05 with the blank group), shows that its blood glucose to normal rat does not have obvious influence.
Two, the influence of hyperglycemia animal is tested
Trial drug of the present invention is the same, positive drug is that (BJ Pharmaceutical Co., Ltd. produces insoral, lot number 9402236, the 25mg/ sheet), alloxan (China Drug Co.'s Beijing purchasing and supply station packing, lot number 940525, the 25g/ bottle), the adrenalin hydrochloride injection (Wuhan Pharmaceutical Factory produces, lot number 940404,1mg/ml).
1. carbohydrate tolerance test
48 of rats, fasting 8 hours, with above-mentioned same method measuring blood sugar of blood extracting, just be divided into 6 groups by the euglycemia value, medicine of the present invention is divided into large, medium and small three groups by above-mentioned same dosage, and positive controls gavages insoral 80mg/kg, and normal control group and model control group are irritated stomach isometric(al) normal saline, once a day, successive administration is 7 days.Fasting is 8 hours before the last administration, gives sugared back 0.5,1 and 2 hour with the method measuring blood sugar of blood extracting.The result is as shown in table 3.
Table 3 pair glucose causes influence (mmol/L, n=8, the X ± SD) of rat hyperglycemia
| Group | Before the administration | After giving glucose (hour) | ||
| ??????0.5 | ????????1 | ????????2 | ||
| Normal control | 4.53±0.69 | ?4.57±0.68 | ?4.37±0.74 | ?4.46±0.68 |
| The model contrast | 4.49±0.71 | ?5.64±0.95 * | ?8.65±0.97 *** | ?8.11±0.76 *** |
| The insoral contrast | 4.48±0.71 | ?4.60±0.89 Δ | ?7.01±0.97 ΔΔ | ?6.91±1.05 Δ |
| Medicine of the present invention (heavy dose) | 4.48±0.89 | ?4.79±0.95 | ?7.43±0.83 Δ | ?7.38±0.78 |
| Medicine of the present invention (middle dosage) | 4.53±0.99 | ?5.18±1.19 | ?8.00±1.08 | ?7.86±1.11 |
| Medicine of the present invention (low dose) | 4.45±0.78 | ?5.28±0.92 | ?8.33±0.99 | ?7.93±0.96 |
Annotate: with the normal control group with:
*P＜0.05,
* *P＜0.001,
Compare with model control group:
ΔP＜0.05,
The Δ ΔP＜0.01.
Table 3 result shows, medicine successive administration of the present invention 7 days, and the rat blood sugar that glucose is caused raises certain inhibitory action is arranged, and is wherein only remarkable with heavy dose group (20g/Kg) effect of 1 hour after giving glucose.
2. epinephrine is caused the influence test of rat hyperglycemia
Animal grouping and the same test of basic research method, 1 hour normal control group subcutaneous injection normal saline 0.2ml/100g after the last administration wherein, model group and each administration group subcutaneous injection epinephrine 0.25mg/Kg injected back 1 hour and 2 hours difference measuring blood sugar of blood extracting.The result is as shown in table 4.
Table 4 pair epinephrine causes influence (mmol/L, n=8, the X ± SD) of rat hyperglycemia
| Group | Before the administration | After giving epinephrine (hour) | |
| ?????????1 | ???????????2 | ||
| Normal control | ??4.09±0.78 | ??4.39±0.81 | ??4.29±0.88 |
| The model contrast | ??4.04±0.89 | ??14.09±1.56 *** | ??13.87±1.36 *** |
| The insoral contrast | ??4.07±0.86 | ??11.43±1.86 ΔΔ | ??11.09±1.89 ΔΔ |
| Medicine of the present invention (heavy dose) | ??4.13±0.92 | ??12.04±1.32 Δ | ??11.87±1.47 Δ |
| Medicine of the present invention (middle dosage) | ??4.05±0.88 | ??12.32±1.72 Δ | ??12.26±1.68 |
| Medicine of the present invention (low dose) | ??4.12±0.99 | ??13.25±1.41 | ??13.12±1.43 |
Annotate: compare with the normal control group:
* *P＜0.001; Compare with model control group:
ΔP＜0.05,
The Δ ΔP＜0.01.
Table 4 result shows, medicine successive administration of the present invention 7 days, epinephrine is caused rat blood sugar to raise in various degree reduction effect is arranged, serve as obvious wherein with heavy dose of (20g/Kg) group, after modeling 1 hour with 2 hours its blood glucose values and the same period model group significant difference is more all arranged, but fail to return to the euglycemia level, may be more relevant with model; In dosage (10g/Kg) group hold time shortlyer, only after modeling, with model group significant difference was arranged relatively in 1 hour, low dose of (5g/Kg) group decreases to blood glucose, but not obvious.
3. alloxan is caused the influence test of rat hyperglycemia
Rat fasting 24 hours, the freshly prepared 7.5% alloxan normal saline solution 2ml/Kg (150mg/Kg) of subcutaneous injection, inject and got blood (fasting is 8 hours before getting blood) from the eye socket vascular plexus in back 96 hours, with determination of glucose oxidase blood glucose, choose 72 of the rat of blood glucose more than 10mmol/L, just be divided into 5 groups by blood glucose value, other gets with 12 of batch rats and is the normal control group, by above-mentioned dosage and mode administration, normal and model control group is irritated stomach isometric(al) normal saline, once a day, successive administration 40 days is respectively at administration 10,20,30,40 days with the method measuring blood sugar of blood extracting.The result is as shown in table 5.
Table 5 pair alloxan causes influence (mmol/L, n=12, the X ± SD) of rat hyperglycemia
Annotate: compare with the normal control group:
*P＜0.01,
* *P＜0.001;
| Group | Before the administration | After the administration (my god) | |||
| ????????10 | ?????????20 | ?????????30 | ?????????40 | ||
| Normal control | ??4.94±0.77 | ??5.03±1.02 | ??4.98±1.07 | ??4.90±0.99 | ??5.15±0.98 |
| The model contrast | ??16.74±4.48 *** | ??16.97±6.02 *** | ??18.55±4.33 *** | ??15.31±4.1 *** | ??10.40±2.78 ** |
| The insoral contrast | ??16.75±3.38 | ??12.27±3.30 Δ | ??11.22±2.99 ΔΔΔ | ??9.17±2.82 ΔΔΔ | ??6.94±1.63 ΔΔ |
| Medicine of the present invention (heavy dose) | ??17.15±4.12 | ??14.97±6.05 | ??14.17±3.83 Δ | ??11.54±3.61 Δ | ??7.91±2.63 Δ |
| Medicine of the present invention (middle dosage) | ??16.71±3.56 | ??15.61±3.79 | ??15.62±3.77 | ??12.76±3.48 | ??8.56±2.04 |
| Medicine of the present invention (low dose) | ??16.74±4.29 | ??16.74±4.16 | ??16.37±3.83 | ??13.51±3.81 | ??9.49±3.01 |
Compare with model control group:
ΔP＜0.05,
The Δ ΔP＜0.01,
Δ Δ ΔP＜0.001.
Table 5 result shows, to the rat skin lower injection alloxan, causes hyperglycemia model, by heavy dose of administration of medicine of the present invention 20 days, 30 days and 40 days, the blood glucose of rising is significantly reduced again, with model control group same period P＜0.05 relatively; In pressing, low dose of administration then acts on not remarkable.
Three, to the hemorheological influence of hyperglycemia animal
Each tests medication with above-mentioned test.48 of rats, fasting 24 hours, the freshly prepared 7.5% alloxan normal saline solution 2ml/Kg (150mg/Kg) of subcutaneous injection, inject and got blood (fasting is 8 hours before getting blood) from the eye socket vascular plexus in back 96 hours, with determination of glucose oxidase blood glucose, choose 40 of the rat of blood glucose more than 10mmol/L, just be divided into 5 groups by blood glucose value, other gets with 8 of batch rats and is the normal control group, by above-mentioned dosage and mode administration, normally reach model control group and irritate stomach isometric(al) normal saline, once a day, successive administration 40 days was got blood in 1 hour and is made hemorheology and detect after the last administration.The result is as shown in table 6.
The table 6 pair hemorheological influence of model induced by alloxan hyperglycemic rat (n=8, X ± SD)
| Group | ??????H t | ?????J 1 | ????J 6 | ????J 7 | ????Eh | ?????Ei | ??????Lb | ?????Rh |
| Normal control | ??53.5±3.7 | ??4.61± ????0.98 | ??15.70± ????3.29 | ??1.27± ????0.20 | ??3.13± ????0.60 | ??18.27± ????4.53 | ??10.67± ????1.92 | ??4.03± ????1.33 |
| The model contrast | ??51.7±6.4 | ??6.20± ????1.39 | ??21.29± ????4.71 * | ??1.60± ????0.14 | ??5.01± ????0.79 *** | ??26.88± ????5.52 ** | ??17.15± ????4.69 ** | ??7.63± ????2.76 |
| The insoral contrast | ??53.4±4.4 | ??4.88± ????0.90 Δ | ??16.01± ????3.69 Δ | ??1.37± ????0.10 ΔΔ | ??3.25± ????0.71 ΔΔΔ | ??18.61± ????4.59 ΔΔ | ??10.98± ????2.69 ΔΔ | ??4.36± ????1.21 Δ |
| Medicine of the present invention (heavy dose) | ??52.3±3.4 | ??5.52± ????1.09 | ??18.31± ????3.65 | ??1.36± ????0.21 Δ | ??3.51± ????0.92 ΔΔ | ??20.43± ????5.61 Δ | ??11.70± ????3.09 Δ | ??4.79± ????1.68 Δ |
| Medicine of the present invention (middle dosage) | ??53.1±5.5 | ??5.01± ????0.79 | ??17.31± ????3.83 | ??1.47± ????0.18 | ??3.67± ????0.65 ΔΔ | ??21.60± ????3.81 Δ | ??12.64± ????2.62 Δ | ??4.99± ????0.98 Δ |
| Medicine of the present invention (low dose) | ??54.0±2.5 | ??5.32± ????0.94 | ??17.76± ????3.42 | ??1.47± ????0.16 | ??4.25± ????0.78 | ??24.29± ????4.36 | ??15.38± ????4.21 | ??6.00± ????1.46 |
Annotate: H
1Packed cell volume, J
1The whole blood height is cut viscosity, J
6The low viscosity, J of cutting of whole blood
7Plasma viscosity,
The Eh height is cut reduced viscosity, and Ei is low to cut reduced viscosity, Lb erythrocyte aggregation index, Rh erythrocyte rigidity index.
Compare with the normal control group:
*P＜0.05,
*P＜0.01,
* *P＜0.001;
Compare with model control group:
ΔP＜0.05,
The Δ ΔP＜0.01,
Δ Δ ΔP＜0.001.
Table 6 result shows, the rat diabetes model of model induced by alloxan has tangible hemorheology to change, diabetes rat shows the high and low viscosity of cutting of whole blood, the high and low reduced viscosity of cutting, plasma viscosity, erythrocyte aggregation index and erythrocyte rigidity index obviously raise, and more all have significant difference with matched group.The heavy dose of group treatment of medicine of the present invention 40 days, above-mentioned every index all decreases, wherein plasma viscosity, reduced viscosity and erythrocyte aggregation index and erythrocyte rigidity index reduce significantly, middle dosage group also can significantly reduce reduced viscosity, erythrocyte rigidity index and aggregate index, and small dose group only has effect trend.
Four, the influence of mice hyperlipemia is tested
Trial drug of the present invention is with above-mentioned test; Positive drug is Radix Oenotherae erythrosepalae oil (group of stars pharmaceutical factory in Guangzhou produces, lot number 941202,300mg/ grain), cholesterol (HOLLAND import packing, lot number 940704,100g/ bottle), cholic acid (FLuKa, Analysis 256769189, the 25g/ bottle).
72 of the Male Kunming strain mice of body weight 18-20 gram are divided into 6 groups at random by body weight, normal control group feed normal diet, (normal diet adds 1% cholesterol for model control group and each administration group feed high lipid food, 10% Adeps Sus domestica and 0.3% cholic acid), the experimental session feed does not add restriction, the present invention is big, in, the dosage of little administration group is with above-mentioned test, positive controls is irritated stomach Radix Oenotherae erythrosepalae oil 1.4g/Kg (be a clinical consumption per day 20 times), irritating the stomach volume is 0.2ml/10g, normal control group and model control group are irritated stomach isometric(al) normal saline, be administered once every day, feed high lipid food and gastric infusion were got blood after 40 days, enzymatic assays serum levels of triglyceride and cholesterol.The result is as shown in table 7.
The influence of table 7 pair hyperlipemia in mice triglyceride and cholesterol (n=12, X ± SD)
| Group | Triglyceride (mmol/L) | Cholesterol (mmol/L) |
| Normal control | ????0.60±0.11 | ????2.34±0.24 |
| The model contrast | ????0.99±0.17 *** | ????10.86±2.78 *** |
| The Radix Oenotherae erythrosepalae oil contrast | ????0.82±0.14 Δ | ????7.41±2.32 ΔΔ |
| Medicine of the present invention (heavy dose) | ????0.89±0.19 | ????8.66±2.16 Δ |
| Medicine of the present invention (middle dosage) | ????0.91±0.19 | ????8.54±3.49 |
| Medicine of the present invention (low dose) | ????0.95±0.17 | ????9.06±3.33 |
Annotate: compare with the normal control group:
* *P＜0.001; Compare with model control group:
ΔP＜0.05,
The Δ ΔP＜0.01.
Table 7 result shows, mice feed high lipid food 40 days, serum levels of triglyceride and cholesterol all are significantly higher than normal control group (P＜0.001), the heavy dose group (20g/Kg) of medicine of the present invention all has the reduction effect to serum levels of triglyceride and the cholesterol that raises, wherein with being reduced to significantly to cholesterol, middle dosage group (10g/Kg) also decreases with the triglyceride and the cholesterol of small dose group (5g/Kg) to hyperlipemia in mice, but compares there was no significant difference (P＞0.05) with model group.
Five, the influence of general situation of mice and stress ability is tested
Trial drug of the present invention is with above-mentioned test, and positive drug is TAIYANGSHEN ORAL LIQUID (10ml/ props up for Guangdong TAIYANGSHEN group company product, lot number 940606A6).
1. swimming test
60 of mices are divided into 5 groups at random by body weight, and medicine of the present invention is divided into large, medium and small three dosage groups by above-mentioned test method, and the positive drug matched group is given TAIYANGSHEN ORAL LIQUID by 20ml/Kg, all gastric infusion.Matched group is irritated stomach isometric(al) normal saline, once a day, successive administration 20 days, after the last administration 30 minutes, the bear a heavy burden electric fuse of 3% body weight of every Mus afterbody, putting into water temperature and be 25-26 ℃, the depth of water is the tank of 25cm, observes also the record mice from putting into the time of beginning to dead (sink under water and can not refloat), as swimming continuance time.The result is as shown in table 8.
The influence of table 8 pair mice swimming continuance time (n=12, X ± SD)
| Group | Swimming continuance time (minute) |
| Matched group | ????28.3±6.3 |
| The TAIYANGSHEN ORAL LIQUID contrast | ????36.2±9.0 * |
| Medicine of the present invention (heavy dose) | ????36.8±10.4 * |
| Medicine of the present invention (middle dosage) | ????39.0±14.8 * |
| Medicine of the present invention (low dose) | ????31.3±8.2 |
Annotate: the consumption of TAIYANGSHEN ORAL LIQUID 20ml/Kg is 33 times of a clinical consumption per day.Compare with matched group:
*P＜0.05.
Table 8 result shows, the large, medium and small dosage continuous irrigation stomach mice of medicine of the present invention 20 days, all can prolong the swimming time of mice,, not have significant difference (P＞0.05) with the effect of the TAIYANGSHEN ORAL LIQUID of 20ml/Kg dosage wherein with the acting as significantly of big or middle dosage.
2. normal pressure hypoxia endurance test
60 of mices are divided into 5 groups at random by body weight, an all the same test of the dosage grouping of medicine of the present invention and positive drug and administering mode.Be administered once every day, successive administration 20 days, after the last administration 30 minutes, put volume and be in the wide mouthed bottle that 250ml fills the 15g sodica calx (one every bottle), sealing bottleneck (bottleneck is coated with vaseline), observe also the record mice from putting into the time of bottle to death, i.e. hypoxia endurance time, the result is as shown in table 9.
The influence of table 9 pair mice normal pressure hypoxia endurance time (n=12, X ± SD)
| Group | Hypoxia endurance time (minute) |
| Matched group | ????30.5±6.3 |
| The TAIYANGSHEN ORAL LIQUID contrast | ????39.3±9.4 * |
| Medicine of the present invention (heavy dose) | ????36.0±9.7 |
| Medicine of the present invention (middle dosage) | ????36.3±8.5 |
| Medicine of the present invention (low dose) | ????34.3±8.0 |
Annotate: compare with matched group:
*: P＜0.05.
Table 9 result shows that three dosage groups of medicine of the present invention all prolong to some extent to mice normal pressure hypoxia endurance time, but compares there was no significant difference (P＞0.05) with matched group.
Above-mentioned some materia medica result of the tests are all clear to be demonstrated, medicine of the present invention has the effect of blood sugar lowering to hyperglycemia animal, rat hyperglycemia due to alloxan and the epinephrine there is remarkable reduction effect, glucose is caused the rat blood sugar rising certain antagonism, and normal rat blood sugar is not had obvious influence.Medicine of the present invention has tangible function of promoting blood circulation to disperse blood clots, can improve hemorheology index, significantly reduce plasma viscosity, whole blood reduced viscosity and the erythrocyte aggregation index of alloxan diabetes rat, increase erythrocyte deformability, this medicine all has the reduction effect to the serum levels of triglyceride and the cholesterol of hyperlipemia in mice, act as significantly with the reduction to cholesterol.And medicine of the present invention can also significantly improve endurance and the stress ability of mice.
Six, clinical treatment test
Adopt said medicine of the present invention in different hospitals, to carry out the clinical treatment test to amounting to 420 routine diabetes (type ii diabetes) cases respectively.Wherein, be divided into the treatment group of giving medicine of the present invention and give the matched group of JIANGTANGSHU JIAONANG control drug, the man/women ratio between two groups of cases is respectively 50.67/49.33 and 53.33/46.67, the two there was no significant difference (P＞0.05); The age distribution of two groups of cases includes＜and 40 years old～65 years old, the mean age between group distributes does not have significant difference (P＞0.05) yet; The course of disease of two groups of cases includes＜1 year～5 years surplus, the also there was no significant difference (P＞0.05) that distributes of the average course of disease between group; The fasting glucose that two groups of cases are carried out, 2 hours after the meal blood glucose and glucose in urine are quantitative, meansigma methods there are no significant equally difference (being P＞0.05) between the group of every detection indexs such as cholesterol, triglyceride and the high density lipoprotein before the treatment, glycolated hemoglobin.Between two groups, comprise the lazy speech of breathing hard, spontaneous sweating, dysphoria with feverish sensation in the chest palms and soles as fatigue and weakness, thirst and liking drink, vexed in the heart pain, numb limbs and tense tendons or twinge, constipation, traditional Chinese medical science primary symptom such as picture of the tongue and abnormal pulse condition and symptom integral and average relatively, also there was no significant difference (P＞0.05).
Case is judged and is selected, outside determining divided by traditional Chinese medical discrimination diagnostic criteria, and employing WHO tentative standard (1980), allly meet one of following condition person and promptly be diagnosed as diabetes (but get rid of the type i diabetes of insulin-dependent, and because of other cases that are not suitable for testing such as health, age, noncooperationists):
1. diabetic symptom is arranged, blood glucose 〉=11.1mmol/L (200mg/dl), or fasting glucose 〉=7.8mmol/L (140mg/dl) any time;
2. diabetic symptom is arranged and blood glucose does not reach above-mentioned standard, carry out 75g oral glucose tolerance test (OGTT), 2 hours blood glucose 〉=11.1mmol/L (200mg/dl);
3. as the non-diabetic symptom, remove above-mentioned standard exterior palpi and add a standard in addition, be 1 hour blood glucose 〉=11.Lmmol/L (200mg/dl) of OGTT, or 2 hours blood glucose 〉=11.1mmol/L (200mg/dl) of another time OTGG, or another time fasting glucose 〉=7.8mmol/L (140mg/dl).
Trial drug is respectively said medicine of the present invention, and every day three times is oral, each 5 grams; Control drug is a JIANGTANGSHU JIAONANG, every day three times, each 5.Be 2 months the course of treatment.
Curative effect judging standard:
1. blood sugar lowering curative effect:
Produce effects: fasting glucose＜7.2mmol/L (130mg/dl), 2 hours after the meal blood glucose＜8.3mmol/L (150mg/dl), twenty-four-hour urine sugar quantitatively＜10.0g; Or blood glucose, twenty-four-hour urine sugar quantitatively descends more than 30% before the treatment;
Effectively: fasting glucose＜8.3mmol/L (150mg/dl), 2 hours after the meal blood glucose＜10.0mmol/L (180mg/dl), twenty-four-hour urine sugar quantitatively＜25.0g; Or blood glucose, twenty-four-hour urine sugar quantitatively descends more than 10% before the treatment;
Invalid: blood glucose, glucose in urine descend and do not reach above-mentioned standard.
2. tcm syndrome curative effect:
Produce effects: tcm symptom classification integration and treatment back descend 〉=2/3;
Effectively: tcm symptom classification integration and treatment back descend 1/3～2/3;
Invalid: tcm symptom classification integration and treatment back descend＜1/3.
Significance to the efficacy result of two groups of Drug therapys test and statistical procedures is more as shown in table 10; The significance comparative result of the efficacy result of every clinical indices and corresponding statistical procedures is shown in table 1I.
The efficacy result comparative statistics of table 10 liang group Drug therapy
| Test item | Group | Obvious effective rate (%) | Effective percentage (%) | The statistical disposition significance relatively between group |
| The blood sugar lowering curative effect | The treatment group | ????59.33 | ????81.00 | ????P＜0.01 |
| Matched group | ????25.83 | ????67.50 | ||
| The tcm syndrome curative effect | The treatment group | ????59.67 | ????86.67 | ????P＜0.01 |
| Matched group | ????33.33 | ????66.67 |
Every clinical indices efficacy result comparative statistics of table 11 liang group Drug therapy
| Clinical indices | Group | Detected value (X ± SD) | Statistical significance relatively between the group of treatment front and back difference | ||
| Before the treatment | After the treatment | Difference | |||
| Fasting glucose (mmol/L) | The treatment group | ??11.84±3.72 | ?8.83±3.10 | ??3.02±1.54 | ????P＜0.01 |
| Matched group | ??11.41+3.12 | ?9.81±2.86 | ??1.65±1.19 | ||
| 2 hours after the meal blood glucose (mmol/L) | The treatment group | ??16.46±5.15 | ?11.35±3.74 | ??5.13±2.02 | ????P＜0.01 |
| Matched group | ??16.02±4.87 | ?13.75±3.14 | ??2.28±1.28 | ||
| Twenty-four-hour urine sugar quantitatively | The treatment group | ??22.62±9.24 | ?12.30±8.61 | ??10.35±5.13 | ????P＜0.01 |
| Matched group | ??23.07±8.97 | ?14.41±8.03 | ??8.68±3.82 | ||
| Glycolated hemoglobin | The treatment group | ??12.09±6.25 | ?9.56±2.30 | ??2.52±1.89 | ????P＜0.01 |
| Matched group | ??11.58±5.94 | ?10.45±2.67 | ??1.12±2.42 | ||
| Cholesterol (mmol/L) | The treatment group | ??7.25±0.70 | ?5.89±1.23 | ??1.37±1.43 | ????P＜0.01 |
| Matched group | ??7.12±0.54 | ?6.79±0.87 | ??0.45±0.68 | ||
| Triglyceride (mmol/L) | The treatment group | ??2.97±1.59 | ?2.38±3.04 | ??0.52±0.71 | ????P＜0.01 |
| Matched group | ??2.77±1.40 | ?2.64±1.27 | ??0.16±0.56 | ||
| High density lipoprotein (mmol/L) | The treatment group | ??0.87±0.17 | ?1.14±0.41 | ??-0.26±0.38 | ????P＜0.01 |
| Matched group | ??0.84±0.17 | ?0.89±0.22 | ??-0.03±0.09 | ||
The result of table 10 and table 11 shows, in the contrast therapy test of carrying out with JIANGTANGSHU JIAONANG, medicine of the present invention is 59.33% to the hold concurrently blood sugar lowering curative effect obvious effective rate of syndrome of blood stasis (type ii diabetes) of the deficiency of both QI and YIN in the Chinese medicine syndrome differential diagnosis, and effective percentage is 81.00%; Obvious effective rate to tcm syndrome is 59.67%, and effective percentage is 86.67%, and blood sugar lowering curative effect and tcm syndrome curative effect all obviously are better than the control drug JIANGTANGSHU JIAONANG, learns by statistics and handles, and its difference all has significance (P＜0.01).To the pathogenic QI in the body Yin bivacuity of the quenching one's thirst primary symptom of syndrome of blood stasis of holding concurrently, as fatigue and weakness, the lazyness of breathing hard speech, spontaneous sweating, dysphoria with feverish sensation in the chest palms and soles, thirst and liking drink, vexed in the heart pain, numb limbs and tense tendons or twinge, constipation, diseases such as picture of the tongue and abnormal pulse condition all have better curative effect, wherein to fatigue and weakness, the lazyness of breathing hard speech, spontaneous perspiration, vexed in the heart pain, the curative effect of disease such as numb limbs and tense tendons or twinge and abnormal pulse condition, relatively and by statistics learn processing with the matched group that uses JIANGTANGSHU JIAONANG, its difference has significance, shows that the treatment group of using medicine of the present invention obviously is better than using the matched group of medicine JIANGTANGSHU JIAONANG.Medicine of the present invention has and reduces fasting glucose and the effect of 2 hours blood glucose after the meal preferably, treatment back fasting glucose and 2 hours after the meal blood glucose decline highly significants (P＜0.01), and have and reduce the glucose in urine effect preferably, treatment back twenty-four-hour urine sugar is decline highly significant (P＜0.01) quantitatively.Reduce fasting glucose, 2 hours after the meal blood glucose and twenty-four-hour urine sugar quantitative effect and matched group comparison, difference has utmost point significance (P＜0.01), and the treatment group is better than matched group.In addition, clinical trial is also pointed out, and medicine of the present invention has certain reduction glycolated hemoglobin effect, compares with matched group, and difference has utmost point significance; Medicine of the present invention also has the effect of definite cholesterol reducing and triglyceride, and the effect of high density lipoprotein increasing is arranged, and shows that medicine of the present invention all has tangible Accommodation to the multiple complications that the diabetes disorders of lipid metabolism causes.
Above-mentioned result of the test shows fully that all the pharmaceutical composition of the above-mentioned composition form of the present invention is used for treatment of diabetes and has significant and positive significance and great value.
Claims (9)
1. treat the combination of oral medication of diabetes, it is characterized in that with the Radix Astragali, the Radix Rehmanniae, Radix Paeoniae Rubra, Radix Salviae Miltiorrhizae, Radix Achyranthis Bidentatae, Radix Ophiopogonis, Radix Puerariae, Folium Mori, Rhizoma Coptidis, Rhizoma Polygonati and Herba Epimedii be the active drug composition, mix composition with the auxiliary adding ingredient of oral drug preparation acceptable, the weight portion ratio of each active drug composition is:
Radix Astragali 19-30, Radix Rehmanniae 20-31, Radix Paeoniae Rubra 20-31, Radix Salviae Miltiorrhizae 19-30, Radix Achyranthis Bidentatae 11-18,
Radix Ophiopogonis 11-18, Radix Puerariae 12-20, Folium Mori 12-20, Rhizoma Coptidis 3-6, Rhizoma Polygonati 12-18,
Herba Epimedii 16-22.
2. the combination of oral medication of treatment diabetes as claimed in claim 1 is characterized in that the weight portion ratio of said each active drug composition is:
Radix Astragali 22-26, Radix Rehmanniae 23-29, Radix Paeoniae Rubra 23-29, Radix Salviae Miltiorrhizae 22-26, Radix Achyranthis Bidentatae 13-17,
Radix Ophiopogonis 13-17, Radix Puerariae 13-18, Folium Mori 13-18, Rhizoma Coptidis 4-6, Rhizoma Polygonati 14-17,
Herba Epimedii 18-22.
3. the combination of oral medication of treatment diabetes as claimed in claim 2 is characterized in that the weight portion ratio of said each active drug composition is:
Radix Astragali 23-25, Radix Rehmanniae 25-27, Radix Paeoniae Rubra 25-27, Radix Salviae Miltiorrhizae 23-25, Radix Achyranthis Bidentatae 14-15,
Radix Ophiopogonis 14-15, Radix Puerariae 14-17, Folium Mori 14-17, Rhizoma Coptidis 4-5, Rhizoma Polygonati 14-16,
Herba Epimedii 19-21.
4. the combination of oral medication of treatment diabetes as claimed in claim 1, it is characterized in that in said each ingredient, the Radix Astragali, the Radix Rehmanniae, Radix Paeoniae Rubra and Radix Salviae Miltiorrhizae divide for adopting first of weight portion such as basic to form, Radix Achyranthis Bidentatae, Radix Ophiopogonis, Radix Puerariae, Folium Mori, Rhizoma Polygonati and Herba Epimedii divide for adopting second of weight portion such as basic to form, and each weight portion ratio of forming the one-component between dividing is adopted as the one-component in first group: the one-component in second group: Rhizoma Coptidis equals or is similar to 5: 3: 1.
5. as the combination of oral medication of the described treatment diabetes of one of claim 1 to 4, it is characterized in that the Radix Achyranthis Bidentatae in the said active drug composition is a Radix Achyranthis Bidentatae.
6. as the combination of oral medication of the described treatment diabetes of one of claim 1 to 4, it is characterized in that effective medicinal ingredient in the medicine is is the water extract that raw material obtains by each ingredient by said proportional quantities.
7. the combination of oral medication of treatment diabetes as claimed in claim 7 is characterized in that effective medicinal ingredient in the medicine is is the water extract that raw material obtains with 80 ℃-100 ℃ hot water to each ingredient of said proportional quantities.
8. as the combination of oral medication of the described treatment diabetes of one of claim 1 to 4, it is characterized in that said oral drugs are the solid preparation form.
9. as the combination of oral medication of the described treatment diabetes of one of claim 1 to 4, it is characterized in that said oral drugs are the liquid preparation form.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02128052 CN1245199C (en) | 2002-12-18 | 2002-12-18 | Oral medicinal composition for treating diabetes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02128052 CN1245199C (en) | 2002-12-18 | 2002-12-18 | Oral medicinal composition for treating diabetes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1424063A true CN1424063A (en) | 2003-06-18 |
| CN1245199C CN1245199C (en) | 2006-03-15 |
Family
ID=4745907
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 02128052 Expired - Lifetime CN1245199C (en) | 2002-12-18 | 2002-12-18 | Oral medicinal composition for treating diabetes |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1245199C (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101972315A (en) * | 2010-09-29 | 2011-02-16 | 辽宁奥达制药有限公司 | Traditional Chinese medicinal composition and preparation method and use thereof |
| CN102271698A (en) * | 2009-05-25 | 2011-12-07 | 成都中汇制药有限公司 | Pharmaceutical composition and use for preparing medicament thereof |
| CN105395829A (en) * | 2015-12-08 | 2016-03-16 | 王敏 | Efficient blood sugar lowering drug |
| CN106581277A (en) * | 2017-02-13 | 2017-04-26 | 佛山市腾瑞医药科技有限公司 | Traditional Chinese medicinal composition for treating diabetes, and preparation method thereof |
-
2002
- 2002-12-18 CN CN 02128052 patent/CN1245199C/en not_active Expired - Lifetime
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102271698A (en) * | 2009-05-25 | 2011-12-07 | 成都中汇制药有限公司 | Pharmaceutical composition and use for preparing medicament thereof |
| CN101972315A (en) * | 2010-09-29 | 2011-02-16 | 辽宁奥达制药有限公司 | Traditional Chinese medicinal composition and preparation method and use thereof |
| CN101972315B (en) * | 2010-09-29 | 2012-09-05 | 辽宁奥达制药有限公司 | Use of traditional Chinese medicinal composition |
| CN105395829A (en) * | 2015-12-08 | 2016-03-16 | 王敏 | Efficient blood sugar lowering drug |
| CN106581277A (en) * | 2017-02-13 | 2017-04-26 | 佛山市腾瑞医药科技有限公司 | Traditional Chinese medicinal composition for treating diabetes, and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1245199C (en) | 2006-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1857618A (en) | Chinese medicine preparation for reducing sugar | |
| CN1895547B (en) | Medicine for treating diabetes and its preparation | |
| CN1561994A (en) | Medicinal compositon containing artemisine extract for treating rheumatoid arthritis and immunologic disease | |
| CN101780227B (en) | Traditional Chinese medicine composition for treating acute stroke and preparation method thereof | |
| CN1883640A (en) | Medicine for treating leucocytopenia caused after tumor radiotherapy and chemotherapy | |
| CN1927331A (en) | Chinese medicine preparation for curing chronic heart failure | |
| CN105287812A (en) | Medicine composition for treating irritable bowel syndromes and application of medicine composition | |
| CN104815166A (en) | Traditional Chinese medicine composition for treating diabetes as well as preparation and application of traditional Chinese medicine composition | |
| CN1245199C (en) | Oral medicinal composition for treating diabetes | |
| CN101041037A (en) | Drug for curing diabetes and nephropathy and its preparing method | |
| CN104491459A (en) | Traditional Chinese medicine composition for treating tumors | |
| CN100342888C (en) | Chinese medicine preparation for treating prostatic hyperplasia | |
| CN1742879A (en) | Chinese medicine for reducing blood sugar and preparation thereof | |
| CN103520684B (en) | Traditional Chinese medicine compound for reducing blood sugar | |
| CN101642485B (en) | Application of medical composition containing astragalus root in preparing medicine for treating leucopenia and Henoch-Schonlein Purpura | |
| CN105727089A (en) | Application of medicine composition containing folium artemisiae argyi to preparing medicine for treating irritable bowel syndrome | |
| CN103169868B (en) | A kind of oral medicine Radix Astragali diabetes capsule for the treatment of diabetes and preparation method thereof | |
| CN105343506A (en) | Method for preparing composition for treating type-2 diabetes | |
| CN104983759A (en) | Traditional Chinese medicine composition treating diabetic nephropathy and preparing method thereof | |
| CN1248715C (en) | Stomachic medication and preparation method | |
| CN100339119C (en) | Traditional Chinese medicine prepns. for treating diabete | |
| CN105709082A (en) | Chinese patent medicine thirst-quenching tea used for treating diabetes, and preparation method thereof | |
| CN1333044A (en) | Wasting-thirst hypoglycemic preparation | |
| CN1895341A (en) | Chinese-medicinal preparation for treating cardiovascular and cerebrovascular diseases | |
| CN100349592C (en) | Chinese medicine composition for treating bone disease, its preparation and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: SICHUAN SUNNYHOPE PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: ZHONGHUI PHARMACEUTICAL CO., LTD., CHENGDU CITY Effective date: 20120203 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 610036 CHENGDU, SICHUAN PROVINCE TO: 610041 CHENGDU, SICHUAN PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20120203 Address after: No. 3 high tech Zone Gaopeng road in Chengdu city of Sichuan Province in 610041 Patentee after: Sichuan Shenghe Pharmaceutical Co.,Ltd. Address before: The 610036 West Sichuan city of Chengdu province No. 30 Patentee before: Chengdu Zhonghui Pharmaceutical Co.,Ltd. |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Oral medicinal composition for treating diabetes Effective date of registration: 20141120 Granted publication date: 20060315 Pledgee: China Huarong Asset Management Limited by Share Ltd. Sichuan branch Pledgor: Sichuan Shenghe Pharmaceutical Co.,Ltd. Registration number: 2014510000035 |
|
| PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20180209 Granted publication date: 20060315 Pledgee: China Huarong Asset Management Limited by Share Ltd. Sichuan branch Pledgor: Sichuan Shenghe Pharmaceutical Co.,Ltd. Registration number: 2014510000035 |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20180711 Address after: 611430 Wenjiang District, Chengdu, Sichuan, Chengdu, 66 science and Technology Industrial Development Park, Collins Road Patentee after: Sichuan Bao Jian pharmacy Co.,Ltd. Address before: No. 3 high tech Zone Gaopeng road in Chengdu city of Sichuan Province in 610041 Patentee before: Sichuan Shenghe Pharmaceutical Co.,Ltd. |
|
| CP01 | Change in the name or title of a patent holder | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 611430 Wenjiang District, Chengdu, Sichuan, Chengdu, 66 science and Technology Industrial Development Park, Collins Road Patentee after: Chengdu Beite Danuo Pharmaceutical Co.,Ltd. Address before: 611430 Wenjiang District, Chengdu, Sichuan, Chengdu, 66 science and Technology Industrial Development Park, Collins Road Patentee before: Sichuan Bao Jian pharmacy Co.,Ltd. |
|
| CX01 | Expiry of patent term | ||
| CX01 | Expiry of patent term |
Granted publication date: 20060315 |